Adjunct Faculty
Adjunct faculty typically have an academic or research appointment at another institution and contribute or collaborate with one or more School of Medicine faculty members or programs.
Adjunct rank detailsKerin Adelson, MD
Associate Professor AdjunctDownloadHi-Res Photo
About
Copy Link
Titles
Associate Professor Adjunct
Biography
Dr. Adelson is an Adjunct Associate Professor and was previously Chief Quality Officer for Yale Cancer Center and Smilow Cancer Hospital. Dr. Adelson graduated from Yale University School of Medicine, completed residency at Mount Sinai Medical Center and Fellowship in oncology at Columbia Presbyterian. In her Quality role, Dr. Adelson focused on improving care coordination for all patients treated in the Smilow network, aligning care with national quality metrics, and developing models to enhance patient involvement in decisions about their cancer-care. Dr. Adelson sits on several national committees including the Southwest Oncology group Cancer Delivery Committee, the National Cancer Care Network Policy Committee and the American Society of Clinical Oncology Health Information Technology Committee.
Last Updated on March 17, 2023.
Appointments
Medical Oncology and Hematology
Associate Professor AdjunctPrimary
Other Departments & Organizations
- Internal Medicine
- Medical Oncology and Hematology
- Pusztai Lab
- Yale Cancer Center
Education & Training
- Fellowship
- Columbia University College of Physicians and Surgeons (2007)
- Residency
- Mount Sinai School of Medicine (2003)
- Internship
- Mount Sinai School of Medicine (2001)
- MD
- Yale School of Medicine (2000)
Research
Copy Link
Overview
Dr. Adelson is actively involved in breast cancer clinical research and serves as an investigator on multiple clinical trials.
Medical Research Interests
Breast
ORCID
0009-0004-4507-4502
Research at a Glance
Yale Co-Authors
Frequent collaborators of Kerin Adelson's published research.
Publications Timeline
A big-picture view of Kerin Adelson's research output by year.
Cary P Gross, MD
Maureen Canavan, PhD, MPH
Lajos Pusztai, MD, DPhil
Anne Chiang, MD, PhD
Andrea Silber, MD
Roy S. Herbst, MD, PhD
145Publications
2,267Citations
Publications
2025
SYSTEMIC ANTICANCER THERAPY PRACTICES AT THE END OF LIFE AMONG GYNECOLOGIC ONCOLOGY PATIENTS
Xiang J, Wiese B, Patlovich K, Adelson K, Ratan R, Taylor J. SYSTEMIC ANTICANCER THERAPY PRACTICES AT THE END OF LIFE AMONG GYNECOLOGIC ONCOLOGY PATIENTS. International Journal Of Gynecological Cancer 2025, 35: 102357. DOI: 10.1016/j.ijgc.2025.102357.Peer-Reviewed Original ResearchPrediction of 48-h Intensive Care Unit Mortality in Hospitalized Cancer Patients: Performance of the EPIC Deterioration Index and Sequential Organ Failure Assessment Score
Leung C, Cheng L, Walton N, Nortje N, Adelson K, Hui D. Prediction of 48-h Intensive Care Unit Mortality in Hospitalized Cancer Patients: Performance of the EPIC Deterioration Index and Sequential Organ Failure Assessment Score. Journal Of Intensive Care Medicine 2025 DOI: 10.1177/08850666251386399.Peer-Reviewed Original ResearchAltmetricConceptsSequential Organ Failure AssessmentSequential Organ Failure Assessment scoreNegative predictive valueIntensive care unit mortalityPositive predictive valueIntensive care unitArea under the receiver operating characteristic curveOptimal cut-off thresholdIntensive care unit transferHospitalized cancer patientsICU mortalityCancer patientsCut-off thresholdsOrgan Failure Assessment scorePredictive valueHigh negative predictive valueICU transferLow positive predictive valueOrgan Failure AssessmentMultivariate logistic regression modelReceiver operating characteristic curveEpic Deterioration IndexOperating characteristics curvePrognostic scoreLogistic regression modelsAssociation of systemic anticancer treatment (SACT) with end-of-life (EOL) healthcare use among older patients with hematologic malignancies.
Xiang J, Cheng L, Canavan M, Lin J, Hui D, Ratan R, Flowers C, Niu J, Zhao H, Giordano S, Adelson K. Association of systemic anticancer treatment (SACT) with end-of-life (EOL) healthcare use among older patients with hematologic malignancies. JCO Oncology Practice 2025, 21: 306-306. DOI: 10.1200/op.2025.21.10_suppl.306.Peer-Reviewed Original ResearchConceptsEnd-of-lifeAcute care useDay of deathHospice useTargeted therapyHealthcare useCare useHematological cancersOlder patientsEnd-of-life careEnd-of-life outcomesICU useHigh healthcare useAssociated with lower qualityER visitsAssociated with higher oddsAnticancer treatmentAssociated with significantly higher ratesQuality of lifeEOL careMultivariate logistic regressionEOL outcomesMonths of lifeChi-square testSignificantly higher ratesTransitional care management for cancer patients: Extending general models of population health management to an oncology specific population.
Jackson L, Huey R, Manzano J, Pantoja L, Skinner N, Bivens D, Rivera J, Adelson K. Transitional care management for cancer patients: Extending general models of population health management to an oncology specific population. JCO Oncology Practice 2025, 21: 282-282. DOI: 10.1200/op.2025.21.10_suppl.282.Peer-Reviewed Original ResearchConceptsTransitional care managementCare managementReadmission ratesPatient challengesTransitional care management programPopulation health managementCare management modelClinical guidancePilot study periodPilot studySpecific populationsUnadjusted odds ratioPost-discharge periodStudy periodMedication reconciliationTelephone outreachEscalation pathwaysPilot periodGuidance of physiciansUnmet needsOdds ratioContact patientsService deliveryMedical guidanceCareThe metric matters: Comparing end-of-life (EOL) systemic anticancer therapy use (SACT) in two quality indicators.
Xiang J, Harris J, Altschuld M, Lin J, Hui D, Wiese B, Patlovich K, Adelson K, Ratan R. The metric matters: Comparing end-of-life (EOL) systemic anticancer therapy use (SACT) in two quality indicators. JCO Oncology Practice 2025, 21: 307-307. DOI: 10.1200/op.2025.21.10_suppl.307.Peer-Reviewed Original ResearchAltmetricConceptsEnd-of-lifeEnd-of-life outcomesCare quality metricsTargeted therapyHematological cancersDeath ageDay of deathEffective careCancer encounterHealth systemInpatient deathOncology hospitalPublic reportingMethodological differencesVizientTherapy useProportion of patientsQuality indicatorsPatient characteristicsPatient inclusionOverall rateAcademic centersMeasurement definitionsASCOImprovement prioritiesIntensity of end-of-life cancer (EOL) care in Medicare Advantage (MA) vs Traditional Medicare (TM).
Xiang J, Niu J, Adelson K, Snyder R, Meyer L, Hui D, Ratan R, Giordano S, Lin J. Intensity of end-of-life cancer (EOL) care in Medicare Advantage (MA) vs Traditional Medicare (TM). JCO Oncology Practice 2025, 21: 309-309. DOI: 10.1200/op.2025.21.10_suppl.309.Peer-Reviewed Original ResearchConceptsEnd-of-life cancerSystemic anticancer therapyMA enrolleesMedicare AdvantageTraditional MedicareHospice useInpatient deathIntensity of EOL careICU useMetastatic cancerCancer care qualityAcute care useER visitsMetastatic solid cancerDays post-diagnosisMultivariate logistic regressionEOL careCare qualityCare useUpstream outcomesPost-diagnosisMedicare enrolleesSolid cancersSEER-MedicareCancer managementPerformance characteristics of CMS' OP-35 quality measure: Sensitive but not specific.
Huey R, Zafar A, Le P, Sanchez N, Patlovich K, Olivieri N, Overman M, Rivera J, Roux R, Adelson K. Performance characteristics of CMS' OP-35 quality measure: Sensitive but not specific. JCO Oncology Practice 2025, 21: 421-421. DOI: 10.1200/op.2025.21.10_suppl.421.Peer-Reviewed Original ResearchAltmetricConceptsSystemic anti-cancer therapyCenters for Medicare and Medicaid ServicesQualifying diagnosisRetrospective reviewUniversity of Texas MD Anderson Cancer CenterMD Anderson Cancer CenterRates of emergency department visitsAnti-cancer therapyEmergency department visitsNo significant differenceMedian lengthCancer CenterPrimary diagnosisDepartment visitsED visitsED dischargeSepsisMedicaid ServicesPneumoniaSignificant differenceSecondary diagnosisDiagnosisPrediction of 48-hour intensive care unit mortality in hospitalized cancer patients: Accuracy of the EPIC deterioration index and sequential organ failure assessment score.
Leung C, Cheng L, Walton N, Nortje N, Adelson K, Hui D. Prediction of 48-hour intensive care unit mortality in hospitalized cancer patients: Accuracy of the EPIC deterioration index and sequential organ failure assessment score. JCO Oncology Practice 2025, 21: 552-552. DOI: 10.1200/op.2025.21.10_suppl.552.Peer-Reviewed Original ResearchConceptsSequential Organ Failure Assessment scoreSequential Organ Failure AssessmentIntensive care unit mortalityNegative predictive valuePositive predictive valueIntensive care unitIntensive care unit transferArea under the receiver operating characteristic curveOptimal cut-off thresholdHospitalized cancer patientsCancer patientsCut-off thresholdsHigh riskOrgan Failure Assessment scorePredictive valueICU transferLow positive predictive valueOrgan Failure AssessmentMultivariate logistic regression modelReceiver operating characteristic curveEpic Deterioration IndexOperating characteristics curvePrognostic scoreLogistic regression modelsPrognostic accuracyStreamlining workflows and optimizing the EHR: Ease of practice project started at a comprehensive cancer center with aims to enhance professional fulfillment.
French K, Bickel J, Renna V, Kheirkhah P, Taiwo V, Tsao A, Adelson K. Streamlining workflows and optimizing the EHR: Ease of practice project started at a comprehensive cancer center with aims to enhance professional fulfillment. JCO Oncology Practice 2025, 21: 598-598. DOI: 10.1200/op.2025.21.10_suppl.598.Peer-Reviewed Original ResearchConceptsProfessional fulfillmentClinical care environmentCancer CenterPilot departmentsComprehensive cancer centerLevels of burnoutLower burnout ratesClinician wellnessPhysician engagementOncology cliniciansCare environmentBaseline surveyElbow supportFocus groupsScheduling teamEHRBurnout ratesDaily frustrationsClinical departmentsClinical workflowMD Anderson Cancer CenterPhysiciansLonger-term solutionsCliniciansStreamlined workflowsAssociation Between Systemic Anticancer Therapy Administration Near the End of Life With Health Care and Hospice Utilization in Older Adults: A SEER Medicare Analysis of End-of-Life Care Quality
Canavan M, Cheng L, Xiang J, Lin J, Hui D, Zhao H, Nortje N, Ratan R, Cherny N, Pham T, Giordano S, Niu J, Adelson K. Association Between Systemic Anticancer Therapy Administration Near the End of Life With Health Care and Hospice Utilization in Older Adults: A SEER Medicare Analysis of End-of-Life Care Quality. Journal Of Clinical Oncology 2025, 43: 3391-3402. PMID: 41004691, DOI: 10.1200/jco-25-00530.Peer-Reviewed Original ResearchThis study investigates the impact of systemic anticancer therapy near the end of life on healthcare and hospice for older adults, showing increased acute care utilization and decreased hospice use, highlighting the need for improved end-of-life care guidelines.
News
Copy Link
News
- January 08, 2026Source: JCO Podcast
Podcast: Association Between EOL SACT and Healthcare Utilization
- October 22, 2025Source: Cure
Improving End-of-Life Care: Making Hospice and Home Support Accessible
- June 07, 2024
Yale Cancer Center Researchers and Trainees Present at ASCO
- March 11, 2024
Oncology Hospitalists Improve Hospice Transitions for Patients with Advanced Cancers
Get In Touch
Copy Link